Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

StrataCTX for Use as a Steroid Sparing Agent in Patients with Skin Reactions Related to Acute GVHD, Cutaneous T Cell Lymphoma and Chemotherapy/Immunotherapy for Solid/Hematologic Malignancies

Trial Status: active

This trial studies how well StrataCTX works as a steroid sparing agent for patients with skin (cutaneous) reactions related to acute graft versus host disease (GVHD), cutaneous T cell lymphoma and chemotherapy/immunotherapy for solid/hematologic malignancies. StrataCTX is a full contact flexible wound dressing which may provide therapeutic relief including decreased itchiness and irritation, and provide relief from topical steroids which are known to thin the skin over time.